Prime Medicine Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of its upsized initial […]